Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy
Keep reading
Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration
